MONTREAL -- (MARKET WIRE) -- February 01, 2007 -- ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) today provided an update on its therapeutic unit, ProMetic BioSciences Inc., which focuses on the development of synthetic drugs in hematology and cancer. This work has given rise to a number of compounds from which the latest compounds, PBI-1737 and PBI-3941, have been selected respectively for preclinical testing in cancer and neutropenia.
